On November 22, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease ("PD"), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, reported that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the Piper Sandler 34th Annual Healthcare Conference being held on November 29 – December 1, 2022, in New York, NY (Press release, Inhibikase Therapeutics, NOV 22, 2022, View Source [SID1234624339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Event: Piper Sandler 34th Annual Healthcare Conference
Presentation Date: Tuesday, November 29, 2022
Presentation Time: 9:10am ET
Location: Lotte New York Palace

A live webcast of the presentation will be accessible on the Company’s website in the Investors section under News & Events at www.inhibikase.com or using the link here. A replay of the webcast will be available on the Inhibikase website for approximately 90 days following the presentation.